As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014.
Through this newly named report series, the PMPRB monitors and reports on:
- the latest developments in generic drug pricing and markets in Canada, in comparison to those of other industrialized countries;
- a broad array of drugs and countries, and analyzes the issue of generic pricing in Canada from various angles, including comparisons to brand-name and international generic prices and a breakdown by market segmentation; and
- the recent trends in Canadian generic pricing at a national level, combining all market segments: public, private and out-of-pocket.
The report highlights that although provincial generic-drug pricing policies and the efforts of the pan-Canadian Pharmaceutical Alliance (pCPA) have played a key role in reducing generic drug prices in Canada, prices remain above international levels.
For more information, please consult the PMPRB’s website.